Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
- 17 May 2010
- journal article
- letter
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 1 (5), 204-208
- https://doi.org/10.1021/ml100051d
Abstract
Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation.Keywords
This publication has 28 references indexed in Scilit:
- E2F1 represses β-catenin transcription and is antagonized by both pRB and CDK8Nature, 2008
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activityNature, 2008
- CDK inhibitors in cancer therapy: what is next?Trends in Pharmacological Sciences, 2008
- Flavopiridol in the treatment of chronic lymphocytic leukemiaCurrent Opinion in Oncology, 2007
- Structure‐guided discovery of cyclin‐dependent kinase inhibitorsPeptide Science, 2007
- In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trialsMolecular Cancer Therapeutics, 2006
- Combined Depletion of Cell Cycle and Transcriptional Cyclin-Dependent Kinase Activities Induces Apoptosis in Cancer CellsCancer Research, 2006
- Unmasking the Redundancy Between Cdk1 and Cdk2 at G2 Phase in Human Cancer Cell LinesCell Cycle, 2006
- Recycling the Cell CycleCell, 2004
- Cancer Cell CyclesScience, 1996